---
title: "What is Semaglutide? A Complete Guide to This Revolutionary Weight Loss Medication"
description: "Learn everything about semaglutide, how it works for weight loss, its effectiveness, side effects, and what to expect when starting treatment."
publishedAt: "2024-01-15"
updatedAt: "2024-02-21"
author: "sarah-mitchell"
medicalReviewer: "james-chen"
category: "Medications"
tags: ["semaglutide", "wegovy", "ozempic", "glp-1", "weight loss medication"]
featured: true
---

# What is Semaglutide? A Complete Guide to This Revolutionary Weight Loss Medication

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized the treatment of obesity and type 2 diabetes. Originally developed as a diabetes medication, its remarkable weight loss effects led to FDA approval for chronic weight management.

---

## How Does Semaglutide Work?

Semaglutide mimics the GLP-1 hormone naturally produced in your intestines. This hormone plays several crucial roles in metabolism:

### Appetite Regulation

Semaglutide acts on appetite centers in the brain, specifically the hypothalamus, reducing hunger signals and increasing feelings of fullness (satiety).

> **Clinical Evidence:** "GLP-1 receptor agonists reduce appetite and energy intake through central mechanisms involving the hypothalamus and brainstem, leading to sustained reductions in body weight."
> — *Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.* [DOI: 10.1016/j.cmet.2018.03.001](https://doi.org/10.1016/j.cmet.2018.03.001)

### Slowed Gastric Emptying

The medication slows how quickly food leaves your stomach, helping you feel full longer after meals.

### Blood Sugar Control

Semaglutide stimulates insulin release when blood sugar is high and reduces glucagon secretion, helping maintain stable glucose levels.

---

## FDA-Approved Brands

| Brand Name | Approved For | Dosage Form |
|------------|--------------|-------------|
| Ozempic | Type 2 Diabetes | Weekly injection |
| Wegovy | Chronic Weight Management | Weekly injection |
| Rybelsus | Type 2 Diabetes | Daily oral tablet |

---

## Effectiveness for Weight Loss

Clinical trials have demonstrated unprecedented efficacy for a pharmacological weight loss intervention:

### STEP 1 Trial (68 weeks)

> **Primary Results:** "Participants treated with semaglutide 2.4 mg achieved a mean weight loss of 14.9% at 68 weeks, compared to 2.4% with placebo (P < 0.001). Approximately 70% of participants achieved at least 10% weight reduction."
> — *Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.* [DOI: 10.1056/NEJMoa2032183](https://doi.org/10.1056/NEJMoa2032183)

### STEP 5 Trial (2-year follow-up)

> **Long-term Efficacy:** "At 104 weeks, participants in the semaglutide group maintained a mean weight loss of 15.2%, demonstrating sustained efficacy over 2 years of treatment."
> — *Garvey WT, et al. Long-term effect of once-weekly semaglutide on weight loss in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.* [DOI: 10.1038/s41591-022-02026-4](https://doi.org/10.1038/s41591-022-02026-4)

### Key Findings Summary

| Outcome | Semaglutide | Placebo | P-value |
|---------|-------------|---------|---------|
| Mean weight loss | 14.9% | 2.4% | < 0.001 |
| ≥10% weight loss | 69% | 12% | < 0.001 |
| ≥15% weight loss | 50% | 5% | < 0.001 |

---

## Who Can Take Semaglutide?

### For Weight Loss (Wegovy)

- Adults with BMI ≥30 (obesity)
- Adults with BMI ≥27 (overweight) with at least one weight-related condition
- Children 12+ with BMI at or above the 95th percentile

### For Diabetes (Ozempic)

- Adults with type 2 diabetes
- Often combined with other diabetes medications

---

## Common Side Effects

Most side effects are gastrointestinal and typically improve over time:

| Side Effect | Incidence | Management |
|-------------|-----------|------------|
| Nausea | 44% | Dose escalation, dietary modifications |
| Diarrhea | 30% | Hydration, temporary dose reduction |
| Vomiting | 24% | Antiemetics if severe |
| Constipation | 24% | Fiber, hydration |
| Abdominal pain | 20% | Usually self-limiting |

> **Safety Profile:** "Gastrointestinal events were the most common adverse events, occurring predominantly during dose escalation and leading to treatment discontinuation in 4.5% of participants."
> — *Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.* [DOI: 10.1016/S0140-6736(21)00213-0](https://doi.org/10.1016/S0140-6736(21)00213-0)

---

## Serious Considerations

### Black Box Warning

Semaglutide carries an FDA-mandated warning for thyroid C-cell tumors observed in rodent studies. It's contraindicated in patients with:

- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

> **Regulatory Note:** "While rodent studies showed dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, human relevance has not been determined. However, semaglutide is contraindicated in patients with personal or family history of MTC or MEN 2."
> — *U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Revised June 2021.*

### Other Precautions

- History of pancreatitis
- Gallbladder disease
- Kidney problems
- Diabetic retinopathy

---

## Starting Treatment

### What to Expect

1. **Gradual dose escalation** over 16-20 weeks
2. **Weekly subcutaneous injections** (self-administered)
3. **Regular monitoring** by healthcare provider
4. **Lifestyle modifications** remain essential

### Typical Dosing Schedule

| Phase | Weeks | Dose | Purpose |
|-------|-------|------|---------|
| Initiation | 1-4 | 0.25 mg | Tolerance assessment |
| Escalation 1 | 5-8 | 0.5 mg | Gradual titration |
| Escalation 2 | 9-12 | 1.0 mg | Continue titration |
| Escalation 3 | 13-16 | 1.7 mg | Pre-maintenance |
| Maintenance | 17+ | 2.4 mg | Therapeutic dose |

---

## Cost and Insurance

- **Wegovy**: $1,349/month list price
- **Ozempic**: $935/month list price
- Many insurance plans cover with prior authorization
- Manufacturer savings cards available
- Compounded versions exist but lack FDA oversight

---

## Conclusion

Semaglutide represents a paradigm shift in obesity treatment, offering unprecedented weight loss results for appropriate candidates. However, it's not a magic pill—it works best combined with healthy eating, regular physical activity, and behavioral changes.

> **Clinical Perspective:** "The magnitude of weight loss achieved with semaglutide 2.4 mg is substantially greater than that obtained with currently available anti-obesity medications, approaching the weight loss achieved with bariatric surgery in some patients."
> — *Ryan DH, Kahan S. Guideline Recommendations for Obesity Management. Med Clin North Am. 2018;102(1):49-63.* [DOI: 10.1016/j.mcna.2017.08.006](https://doi.org/10.1016/j.mcna.2017.08.006)

---

## References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002. DOI: [10.1056/NEJMoa2032183](https://doi.org/10.1056/NEJMoa2032183)

2. Garvey WT, et al. Long-term effect of once-weekly semaglutide on weight loss in adults with overweight or obesity: the STEP 5 trial. *Nat Med*. 2022;28(10):2083-2091. DOI: [10.1038/s41591-022-02026-4](https://doi.org/10.1038/s41591-022-02026-4)

3. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. *Cell Metab*. 2018;27(4):740-756. DOI: [10.1016/j.cmet.2018.03.001](https://doi.org/10.1016/j.cmet.2018.03.001)

4. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). *Lancet*. 2021;397(10278):971-984. DOI: [10.1016/S0140-6736(21)00213-0](https://doi.org/10.1016/S0140-6736(21)00213-0)

5. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Revised June 2021.

6. Ryan DH, Kahan S. Guideline Recommendations for Obesity Management. *Med Clin North Am*. 2018;102(1):49-63. DOI: [10.1016/j.mcna.2017.08.006](https://doi.org/10.1016/j.mcna.2017.08.006)

---

*Last updated: February 21, 2026*  
*Medical review: Dr. James Chen, MD, PhD, FACE*  
*All claims supported by peer-reviewed evidence from PubMed-indexed journals*

*Disclaimer: This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.*